Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Läubli, Heinz ^a,c   Balmelli, Cathrin ^a   Bossard, Matthias ^a   Pfister, Otmar ^a   Glatz, Kathrin ^b   Zippelius, Alfred ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Anti tumor T cell response; Antibody; Autoimmunity; Immunotherapy; Melanoma; Myocarditis; Nivolumab; PD 1 blockade; Pembrolizumab

Indexed keywords

BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; PEMBROLIZUMAB; PREDNISONE; SPIRONOLACTONE; TRANSCRIPTION FACTOR FOXP3; TROPONIN T;

ACUTE HEART FAILURE; AGED; ARTICLE; AUTOIMMUNE MYOCARDITIS; CASE REPORT; CD8+ T LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; LEG EDEMA; LYMPHOCYTIC INFILTRATION; METASTATIC UVEA MELANOMA; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TRANSTHORACIC ECHOCARDIOGRAPHY; UVEA MELANOMA;

EID: 84997637224     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0057-1     Document Type: Article

References (23)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-4.
2. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65:185-202.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
4. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
5. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2015;372:311-9.
6. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-17.
7. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med: Waxman IM; 2014.
8. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-44.
9. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
11. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-33.
12. Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol. 2014;5:206.
13. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-7.
14. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558-62.
15. Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature. 2014;515:496-8.
16. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100:4712-7.
17. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319-22.
18. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477-83.
19. Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22:443-52.
20. Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188:4876-84.
21. Sagar S, Liu PP, Cooper LTJ. Myocarditis. Lancet. 2012;379:738-47.
22. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59:779-92.
23. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29:2073-82.